MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE:MDT), today announced that the U.S. Food and Drug Administration (FDA) has granted pre-market approval (PMA) to its new Specify™ 5-6-5 surgical lead for neurostimulation therapy, a safe and effective treatment for chronic pain that uses the company’s extensive line of implantable neurostimulation systems, including the RestoreADVANCED® and PrimeADVANCED® neurostimulators.
